Ozempic & Mounjaro: Same Shot. Opposite Results.
A physician's lecture on why GLP-1 medications such as semaglutide and tirzepatide lead to different outcomes in different people, with a phenotype framework and a protocol he calls the Thrive Protocol.
With Dr. Amin Hedayat (MD, triple board certified physician and assistant clinical professor)
Key moments
Tap a moment to play the video from there.
- 0:00Same drug, opposite outcomesHedayat opens with two patients on the same medication, one improving and one slowly declining, and says the scale can fall in both cases.
- 2:21Weight loss is not repairHe calls this the one idea to remember, saying weight loss can be a tool for repair or a cosmetic disguise over lost resilience.
- 4:50Four levers of GLP-1 biologyHe covers appetite and reward, gastric emptying, insulin and glucagon, and fat and inflammation, then introduces reserve as the physiological buffer that decides the outcome.
- 14:21The three dial frameworkHe proposes metabolic, reserve and neuroimmune phenotypes as the way to explain who thrives and who struggles.
- 20:17Five deterioration phenotypesHe describes low reserve, motility sensitivity, gallbladder risk, diabetes with eye disease risk, and trauma with dysregulation as groups needing extra protection.
- 28:00Suicidality, surgery, pancreatitisHe says the FDA's preliminary evaluation did not find that these drugs cause suicidal thoughts or actions, that most patients can continue before elective surgery with risk assessment, and that pancreatitis evidence is observational.
- 30:19The Thrive Protocol rulesHe lays out rules on protein, resistance training, gut support, slow titration and watching for warning signs.
- 37:14The off-ramp problemHe cites STEP 1 extension and SURMOUNT-4 data to say weight returns after stopping, and urges an exit plan built well in advance.
What the video says
Dr. Amin Hedayat, who describes himself as a triple board certified physician and assistant clinical professor, argues that weight loss and metabolic repair are not the same thing. His central claim is that the same GLP-1 drug can improve health in one person and erode it in another, even when the scale moves down in both. He frames this as an educational talk, not personal medical advice, and says changes should go through a person's own medical team.
He starts with mechanism. He describes GLP-1 as a gut hormone that coordinates appetite, insulin, glucose handling and digestion, and walks through four levers: appetite and reward circuitry, slowed gastric emptying, insulin and glucagon dynamics, and fat and inflammatory load. He then cites trials as support for the benefits: STEP 1 for weight loss, SELECT for cardiovascular events, and FLOW for kidney outcomes. He stresses that trials report group averages, while his interest is in the spread of individual results.
The core of the video is a three dial model covering metabolic phenotype, reserve phenotype and neuroimmune phenotype. Hedayat says people with high appetite drive, insulin resistance and enough reserve, those whose inflammation is driven by fat, and those at high cardiometabolic risk tend to do well. He lists five groups he thinks are more likely to struggle: low muscle reserve or frailty, gut motility problems, gallbladder risk, diabetes with eye disease risk, and trauma-linked dysregulation. He also gives short takes on suicidality reports and the FDA's January 2026 position, perioperative guidance, and pancreatitis.
The last third is his protocol. It covers protecting lean mass, making protein automatic, resistance training two to four times per week, fiber and hydration, slow dose titration, and watching for warning signs. He adds a pre-start checklist for discussion with a clinician. He closes on the off-ramp, citing trial data that weight tends to return after stopping, and says anyone planning to stop needs an exit strategy built months ahead.
On each compound
Semaglutide11:17
Hedayat cites the STEP 1 trial, where 2.4 mg weekly semaglutide gave about 14.9% mean weight loss at 68 weeks versus about 2.4% with placebo. He also cites SELECT for cardiovascular events and FLOW for kidney outcomes, and says lean mass falls alongside fat mass.
See how your DNA reads SemaglutideTirzepatide22:12
He describes tirzepatide as a dual GIP and GLP-1 agonist with often more average weight loss and a different side effect profile. He says SURMOUNT-1 body composition data showed drops in both fat and lean mass, and that SURMOUNT-4 showed weight regain after withdrawal.
See how your DNA reads Tirzepatide“Weight loss is not the same thing as metabolic repair.”
“GLP-1s can remove the symptom, hunger, without resolving the cause, dysregulation.”
What this video doesn’t settle
- The phenotype framework is the speaker's own model, and the video does not show that these groups reliably predict who thrives or deteriorates.
- Links he draws between childhood trauma, inflammation and GLP-1 response are described by him as a clinical possibility, not something shown in the video.
- The video gives no specific protein targets or titration schedules and defers them to individual clinicians.
Questions this video answers
Why do some people feel worse on GLP-1 medications even while losing weight?
Hedayat says weight loss is not the same as metabolic repair. He argues that people with low reserve, such as low muscle, poor protein intake or high stress, can lose lean mass and function when appetite is strongly suppressed.
What does Dr. Hedayat say about muscle loss on semaglutide or tirzepatide?
He says trials show lean mass decreases, though fat mass falls more, and cites a figure of roughly a quarter of weight loss being lean mass, varying by context. He recommends adequate protein and resistance training two to four times per week.
What happens when you stop a GLP-1 medication according to this video?
Hedayat cites the STEP 1 extension, SURMOUNT-4 and a BMJ review to say that people commonly regain weight and that cardiometabolic improvements tend to move back toward baseline. He says anyone planning to stop needs an exit strategy built months ahead.
Does the FDA say GLP-1 drugs cause suicidal thoughts?
Hedayat says that as of January 13th, 2026, the FDA's preliminary evaluation had not found evidence that these medicines cause suicidal thoughts or actions. He adds that mood changes on treatment should still be taken seriously and raised with a clinician.
Who does Hedayat say may need extra caution with GLP-1 drugs?
He lists people with low muscle reserve or frailty, gut motility problems, prior gallbladder issues, diabetes with eye disease risk, and trauma-linked dysregulation. He says this does not mean avoiding the drug automatically, but building protection into the plan.
Video by Dr. Amin Hedayat, MD on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
